NewAmsterdam Pharma (NAMS) Short Interest Ratio & Short Volume $24.90 -0.07 (-0.28%) (As of 11/15/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NewAmsterdam Pharma Short Interest DataNewAmsterdam Pharma (NAMS) has a short interest of 718,000 shares, representing 1.61% of the float (the number of shares available for trading by the public). This marks a 30.85% increase in short interest from the previous month. The short interest ratio (days to cover) is 2.2, indicating that it would take 2.2 days of the average trading volume of 270,394 shares to cover all short positions.Current Short Interest718,000 sharesPrevious Short Interest548,700 sharesChange Vs. Previous Month+30.85%Dollar Volume Sold Short$12.22 millionShort Interest Ratio2.2 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares90,015,000 sharesFloat Size44,680,000 sharesShort Percent of Float1.61%Today's Trading Volume891,957 sharesAverage Trading Volume270,394 sharesToday's Volume Vs. Average330% Short Selling NewAmsterdam Pharma? Sign up to receive the latest short interest report for NewAmsterdam Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNAMS Short Interest Over TimeNAMS Days to Cover Over TimeNAMS Percentage of Float Shorted Over Time Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. NewAmsterdam Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/2024718,000 shares $12.22 million +30.9%1.6%2.2 $17.02 10/15/2024548,700 shares $10.43 million +23.9%1.3%1.6 $19.00 9/30/2024443,000 shares $7.35 million +4.9%1.0%1.2 $16.60 9/15/2024422,500 shares $6.74 million -77.4%1.0%1.2 $15.96 8/31/20241,870,000 shares $30.71 million +10.7%4.3%5.5 $16.42 8/15/20241,690,000 shares $27.70 million +20.7%4.3%5.3 $16.39 Get the Latest News and Ratings for NAMS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. 7/31/20241,400,000 shares $23.97 million +716.8%3.5%5.8 $17.12 7/15/2024171,400 shares $3.36 million -22.4%0.4%1 $19.59 6/30/2024220,800 shares $4.24 million -15.0%0.6%1.2 $19.21 6/15/2024259,600 shares $4.98 million +5.4%0.7%1.5 $19.19 5/31/2024246,200 shares $4.62 million -10.3%0.6%1.4 $18.75 5/15/2024274,600 shares $5.44 million -26.8%0.4%1.5 $19.81 4/30/2024375,000 shares $8.18 million +11.9%1.0%1.7 $21.81 4/15/2024335,200 shares $6.62 million -0.8%0.9%1.4 $19.74 3/31/2024337,900 shares $7.99 million -1.9%0.9%1.4 $23.65 3/15/2024344,600 shares $7.59 million -6.0%1.0%1.5 $22.03 2/29/2024366,700 shares $8.38 million +38.3%1.1%1.7 $22.84 2/15/2024265,200 shares $5.22 million -2.7%0.8%1.3 $19.67 1/31/2024272,500 shares $5.58 million -44.0%0.8%1.8 $20.47 1/15/2024486,200 shares $8.52 million +16.0%1.5%3.1 $17.53 12/31/2023419,300 shares $4.68 million -1.9%1.3%3.8 $11.17 12/15/2023427,500 shares $4.59 million +114.7%1.2%3.9 $10.74 11/30/2023199,100 shares $1.94 million -3.8%0.6%1.7 $9.76 11/15/2023206,900 shares $2.06 million -43.8%0.6%2.1 $9.95 10/31/2023367,800 shares $3.31 million +267.8%1.1%2.6 $9.00 10/15/2023100,000 shares $725,000.00 -72.7%0.3%0.9 $7.25 9/30/2023366,200 shares $3.39 million +12.1%1.1%3.5 $9.25 9/15/2023326,700 shares $3.27 million +1.0%1.0%3.2 $10.00 8/31/2023323,600 shares $3.34 million -0.5%0.9%3.2 $10.31 8/15/2023325,100 shares $3.58 million +29.7%0.9%3 $11.00 7/31/2023250,700 shares $2.89 million -0.4%0.7%3.7 $11.52 7/15/2023251,700 shares $3.01 million -12.7%0.7%3.6 $11.96 6/30/2023288,400 shares $3.43 million +53.3%0.8%4.2 $11.89 6/15/2023188,100 shares $2.29 million +3.2%0.5%3.1 $12.17 5/31/2023182,200 shares $2.53 million -47.5%0.6%3.9 $13.86 5/15/2023347,300 shares $4.29 million No Change1.1%10.2 $12.34 NAMS Short Interest - Frequently Asked Questions What is NewAmsterdam Pharma's current short interest? Short interest is the volume of NewAmsterdam Pharma shares that have been sold short but have not yet been covered or closed out. As of October 31st, investors have sold 718,000 shares of NAMS short. 1.61% of NewAmsterdam Pharma's shares are currently sold short. Learn More on NewAmsterdam Pharma's current short interest. What is a good short interest ratio for NewAmsterdam Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NAMS shares currently have a short interest ratio of 2.0. Learn More on NewAmsterdam Pharma's short interest ratio. What is a good short interest percentage for NewAmsterdam Pharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.61% of NewAmsterdam Pharma's floating shares are currently sold short. Is NewAmsterdam Pharma's short interest increasing or decreasing? NewAmsterdam Pharma saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 718,000 shares, an increase of 30.9% from the previous total of 548,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is NewAmsterdam Pharma's float size? NewAmsterdam Pharma currently has issued a total of 90,015,000 shares. Some of NewAmsterdam Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. NewAmsterdam Pharma currently has a public float of 44,680,000 shares. How does NewAmsterdam Pharma's short interest compare to its competitors? 1.61% of NewAmsterdam Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to NewAmsterdam Pharma: Roivant Sciences Ltd. (12.38%), Ascendis Pharma A/S (5.62%), Legend Biotech Co. (8.70%), Elanco Animal Health Incorporated (2.81%), Viking Therapeutics, Inc. (11.92%), Cytokinetics, Incorporated (13.75%), Blueprint Medicines Co. (6.50%), Lantheus Holdings, Inc. (6.03%), Nuvalent, Inc. (12.72%), Avidity Biosciences, Inc. (12.29%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short NewAmsterdam Pharma stock? Short selling NAMS is an investing strategy that aims to generate trading profit from NewAmsterdam Pharma as its price is falling. NAMS shares are trading down $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against NewAmsterdam Pharma? A short squeeze for NewAmsterdam Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NAMS, which in turn drives the price of the stock up even further. How often is NewAmsterdam Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NAMS, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies ROIV Short Interest Data ASND Short Interest Data LEGN Short Interest Data ELAN Short Interest Data VKTX Short Interest Data CYTK Short Interest Data BPMC Short Interest Data LNTH Short Interest Data NUVL Short Interest Data RNA Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NAMS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.